Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen

Lead sponsor

US Department of Veterans Affairs

Asset

estrogen

Listed sites

Recruiting sites

Enrollment

Study population

Alzheimer’s disease

Key I/E criteria

•Age 50-90•Female

Primary endpoint

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDAGCG-007-97F

NCT IDNCT00018343

Timeline

Milestones

Study start1998-04 (month precision)

Study completion2001-03 (month precision)

Study first posted2001-07-05estimated

Last update posted2009-01-21estimated

Assets

Drug assets

estrogen

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

Maximum age90 Years

SexFemale

Healthy volunteersNot accepted

Eligibility criteria

•Post menopausal women with alzheimer's disease

•free of any major medical or neurological disease,

•medically safe to be treated with estrogen.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.